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Abstract
Background: Frequent painful vaso-occlusive crises (VOCs) were associated with mortality in the Cooperative Study
of Sickle Cell Disease (CSSCD) over twenty years ago. Modern therapies for sickle cell anemia (SCA) like
hydroxyurea are believed to have improved overall patient survival. The current study sought to determine the
relevance of the association between more frequent VOCs and death and its relative impact upon overall mortality
compared to other known risk factors in a contemporary adult SCA cohort.
Methods: Two hundred sixty four SCA adults were assigned into two groups based on patient reported outcomes for
emergency department (ED) visits or hospitalizations for painful VOC treatment during the 12 months prior to
evaluation.
Results: Higher baseline hematocrit (p = 0.0008), ferritin (p = 0.005), and HDL cholesterol (p = 0.01) were
independently associated with 1 or more painful VOCs requiring an ED visit or hospitalization for acute pain. During a
median follow-up of 5 years, mortality was higher in the ED visit/hospitalization group (relative risk [RR] 2.68, 95% CI
1.1-6.5, p = 0.03). Higher tricuspid regurgitatant jet velocity (TRV) (RR 2.41, 95% CI 1.5-3.9, p < 0.0001), elevated
ferritin (RR 4.00, 95% CI 1.8-9.0, p = 0.001) and lower glomerular filtration rate (RR=2.73, 95% CI 1.6-4.6, p <
0.0001) were also independent risk factors for mortality.
Conclusions: Severe painful VOCs remain a marker for SCA disease severity and premature mortality in a modern
cohort along with other known risk factors for death including high TRV, high ferritin and lower renal function. The
number of patient reported pain crises requiring healthcare utilization is an easily obtained outcome that could help to
identify high risk patients for disease modifying therapies.
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Introduction
Sickle cell disease (SCD) is the most common monogenic
disease in the United States, resulting from mutations in the
beta-subunit of the hemoglobin molecule. Acute episodes of
pain or vaso-occlusive crises (VOCs) are a protean hallmark of
SCD with economic impact due to the cost of unscheduled
health care[1]. Acute VOCs are due to erythrocyte
microvascular occlusion and tissue hypoxia, especially in sickle
cell anemia (SCA)[2]. Inter-individual differences in severe
VOCs leading to utilization of acute care are more common in a
sub-group with frequent pain[3–6]. Reasons for this variability
have not been elucidated, but higher hematocrit and lower fetal
hemoglobin (HbF) are strong predictors for frequent VOCs[4].
Frequent VOCs defined by physician treatment and a duration
of more than 2 hours were associated with higher mortality in
the Cooperative Study of Sickle Cell Disease (CSSCD)
although this association has not been evaluated in
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contemporary populations where health care utilization for
acute painful episodes remains common despite the availability
of SCA specific treatments[3,4,7].
SCA is characterized by specific complications that are risk
factors for early death, although modern therapies are likely to
have altered the natural history and mortality of SCA[8–10]. In
particular, hydroxyurea (HU) in SCA is an effective medication
to significantly reduce hospitalizations for pain[9,11].
Scheduled chronic transfusion in children at high risk for stroke
prevents both cerebrovascular events and reduces the
prevalence of VOCs[8,12]. Additionally, an elevated tricuspid
regurgitant velocity (TRV) is a risk factor for death in some
series and suggestive of cardiopulmonary disease, although
trials of pulmonary vasodilators have failed to demonstrate a
clinical benefit[13–17]. Based upon these observations, we
hypothesized that therapies with demonstrated SCA efficacy
like transfusion programs and HU have altered the magnitude
of associations between acute painful episodes, health care
utilization and mortality. We sought to 1) identify markers
associated with VOCs for comparison to established VOC
associations with baseline hemoglobin and HbF expression
and 2) determine if acute painful episodes defined by hospital
based treatment as a patient reported outcome (PRO) are a
relevant measure of disease severity and risk for death in a
contemporary SCA cohort at a single referral institution.
Methods
Study population
Subjects 18 years of age or older were enrolled according to
a protocol for evaluation of adults with SCD after written
informed consent (The Bethesda Sickle Cell Cohort Study,
ClinicalTrials.gov identifier NCT00011648) between
2001-2007[14,18]. The study was conducted in accordance
with the Declaration of Helsinki and was approved by the
National Heart, Lung and Blood Institute Institutional Review
Board. Recruitment was through advertisement and community
outreach to local clinics, providers, advocacy groups and
patients. Those receiving modern therapies like transfusions
and HU were not excluded. Subjects with any acute
complication in the 2 weeks prior to evaluation were not
enrolled, although recruitment was permitted at a later date.
Data collection included a history, physical examination and
transthoracic echocardiogram as previously described[14,18].
Steady state hemoglobin, fetal hemoglobin (HbF), leukocytes,
platelets, reticulocytes, serum lactate dehydrogenase (LDH),
aspartate aminotransferase, bilirubin and ferritin were
determined at the time of enrollment using standard
methodologies. Subjects were surveyed for the number of
severe acute painful events requiring treatment by a physician
in an emergency department or as a hospital inpatient during
the 12 months prior to evaluation as a PRO. After enrollment,
subjects were contacted at 2 year intervals through 2010 to
document survival. Death certificates and the Social Security
Death Master File were used for additional documentation.
Observations, patient reported outcomes and
definitions
Analysis of VOCs was restricted to subjects with SCA where
the diagnosis was made by DNA sequencing, hemoglobin
electrophoresis and/or high-performance liquid
chromatography[18]. The presence of co-existing α-
thalassemia was determined by multiplex polymerase chain
reactions as previously described[18,19]. “Severe” VOCs were
defined as patient reported emergency department visits or
hospitalizations for pain treatment during the 12 months prior to
enrollment[20]. Neither painful episodes occurring at home
without medical intervention nor hospitalizations for other SCA
complications without acute pain were included in this
definition. HU therapy was recorded dichotomously based upon
treatment decisions made by primary healthcare providers.
Glomerular filtration rate (GFR) was calculated using the
abbreviated Modification of Diet in Renal Disease (MDRD)
equation[21].
Pain history and group assignment
For this report, the number of PRO painful VOCs, as defined
above, were used to categorize subjects into 2 groups: low
VOC (0 emergency department visits/hospitalizations for pain)
and high VOC (≥1 events during the prior 12 months)
groups[4]. The high pain group was compared to all others.
Statistical analysis
Continuous data comparisons were by Wilcoxon or
Pearson’s χ2 test between VOC groups with p values. Using
selected variables significant by univariate analysis, we
identified a logistic regression model by stepwise backward
elimination where all variables had an α ≤ 0.05. Regression
odds ratios compared the 75th relative to 25th percentiles for
continuous variables calculated as e(coefficient)(75th percentile – 25th
percentile). Survival analyses utilized Kaplan-Meier and Cox
proportional hazards modeling. The proportional hazards
assumption was met as tested by the linearity of the rescales
Schoenfeld residuals of the time dependent covariates. Two
sided α’s ≤ 0.05 defined statistical significance with Bonferroni
correction are presented for comparison. Analyses were
performed with Prism (Graph Pad Software, San Diego, CA), R
(http://CRAN.R-project.org), SAS 9.1.3 (Cary, NC), STATA 9.0
(College Station, TX) and SVS (Golden Helix, Bozeman, MT).
Results
Participants
Two hundred sixty four SCA subjects with VOC PRO data
were available for analysis in the current study from a
population of 400 SCD subjects evaluated. The median age of
SCA participants was 32 years and 126 (47%) were male.
Forty one percent of individuals reported HU treatment and 39
% reported receiving more than 10 red cell transfusions during
their lifetime.
Pain and Mortality in Sickle Cell Anemia
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Severe painful episodes and clinical / laboratory
characteristics
The characteristics of the SCA VOC groups are shown in
Table 1. One hundred and sixty study participants (60%)
reported at least one severe VOC requiring hospital based
treatment in the 12 months preceding enrollment and 22% of
individuals in this group reported 5 or more such events. A
patient reported history of asthma, acute chest syndrome, and
priapism was not different between VOC groups, nor was the
proportion of individuals with concurrent α-thalassemia.
Although not statistically significant, a higher proportion of
study participants in the high pain crisis group were on HU,
more likely to have received > 10 red cell transfusions and
have had 1 or more episodes of acute chest syndrome.
Individuals in the frequent ED/hospitalization group had higher
median hemoglobin concentration (9.2 vs. 8.4 g/dL; P=0.0007)
and serum ferritin (618 vs. 313 mg/L; P=0.009), while serum
lactate dehydrogenase (LDH) (346 vs. 378 U/L; P=0.004) and
uric acid (5.5 vs. 6.20 mg/dL; P=0.03) were lower. Fetal
hemoglobin concentration was not different between the
groups (7.7 vs. 6.9%; P=0.3). The proportion of study subjects
with an elevated tricuspid regurgitation velocity (TRV) ≥ 2.5 m/
sec, a previously described marker of suspected
cardiopulmonary disease in adults with SCA[8,13], was not
different between the groups. We further compared the 2 pain
crisis sub-groups with 1-4 ED visits/hopitalizations and greater
than 4 ED visits/hopitalizations to those with less frequent
events (Table S1). Comparison of these 3 groups showed
significant differences for hemoglobin concentration
(P<0.0001), ferritin (P=0.02) and LDH (P=0.009), although
none were not significantly different by pairwise comparison of
the 2 pain crisis groups suggesting that further sub-
classification of the pain crisis groups is not helpful for
identifying additional associations with VOCs. As shown in
Table 2, higher hemoglobin (OR 2.04, 95% CI: 1.3-3.1,
P=0.001), serum ferritin (OR 2.2, 95% CI: 1.3-3.7, P=0.003)
and HDL cholesterol (OR 1.56, 95% CI: 1.1-2.2, P=0.01) were
independently associated with 1 or more severe painful
episodes that required an ED visit or hospitalization by multiple
logistic regression analysis.
Patient reported severe pain crises are an independent
risk factor for mortality in adults with SCA
To determine if severe pain crises remain a risk factor for
early mortality in contemporary SCA patients, univariate
survival analysis was performed. During a median follow-up of
4.92 years, 40 (15.1%) subjects died and 9 (3.4%) were lost to
follow-up. Kaplan-Meier showed a younger age at death in the
high VOC group (55.8 vs. 66.2 years; P=0.04) (Figure 1).
Kaplan-Meier also showed a significant difference when
comparing 3 pain sub-groups (0 ED visits/hospitalizations, 1-4
ED visits/hopitalizations and ≥5 ED visits/hospitalizations)
(P=0.02 for trend, Figure S1). Because the Kaplan Meier
curves comparing the 2 pain groups (1-4 versus ≥5 ED visits/
hospitalizations) were not significantly different (P=0.22, Figure
S1), a Cox proportional hazards analysis of mortality utilized
the categorical high (≥1 ED visits/hospitalizations) versus low
VOC group classification. The risk of death among 208
evaluable subjects with 35 deaths during follow-up by
proportional hazards modeling was again significantly higher
with more than 1 severe VOC during the past 12 months
(relative risk [RR] 2.68, P= 0.03), a higher TRV (RR 2.41,
P<0.0001), elevated ferritin (RR 4.00, P=0.001) and low
estimated glomerular filtration rate (RR 2.73, P<0.0001) (Table
3).
Discussion
We examined VOCs with healthcare utilization and their
association with mortality in a contemporary SCA cohort with a
high prevalence of HU treatment, a therapy that was not
available to subjects included in the first report of this
association[4]. We also describe clinical and laboratory
characteristics associated with patient reported severe VOCs
resulting in an ED visit or hospitalization. Although other SCD
genotypes (hemoglobin SC and S beta plus thalassemia)
experience vaso-occlusive pain, the present analysis was
restricted to sickle cell anemia (homozygous hemoglobin S)
due to well known differences in laboratory parameters and the
frequency of pain between these genotypes[4,7,22]. In our
cohort, about 40% of individuals with SCA reported the
absence of hospital admissions or acute treatment in an ED for
severe VOCs in the 12 months prior to their initial evaluation on
this study, while 22 % reported 5 or more ED visits or
hospitalizations during the same time period. These findings
highlight the variability of severe painful VOCs within a single
genotype despite modern availability of SCD specific therapies.
Despite reports of overall improved survival in SCD, VOC
remains associated with premature death similar to results of
the CSSCD and likely remains a suitable marker of disease
severity[4,7]. The association of higher steady state
hemoglobin with VOCs again replicates a key observation from
the CSSCD, likely due to the effect of higher viscosity in
promoting microvascular sludging and vaso-occlusion[23,24].
The association of higher LDH with the no ED visit/
hospitalization group shows a strong negative correlation
between LDH and hemoglobin, although their effects were not
independent of one another by logistic regression. Our finding
of higher iron burden in the ED visit/ hospitalization group could
reflect the higher number of red cell transfusions reported by
this group. Worsening of anemia is a frequently observed
complication of acute painful VOCs which is often treated with
red cell transfusions in a hospital setting. High ferritin could
also be a reflection of a high inflammatory state in this group,
although other inflammatory markers were not significantly
elevated in this high VOC group. Finally, higher HDL
cholesterol was independently associated with more frequent
VOCs. Hypocholesterolemia is common in SCD and other
anemias and is thought to be a manifestation of increased
erythroid proliferation[25]. Formation of erythroid cell
membranes requires cholesterol, and thus, elevated serum
HDL cholesterol may be a marker of less marrow activity in
those with SCA and a higher hematocrit[26,27]. Additional
studies will be required to determine the mechanism of
hypocholestorolemia in SCA and if this marker is relevant to
the pathophysiology of vaso-occlusion.
Pain and Mortality in Sickle Cell Anemia
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Contrary to the anticipated association, fetal hemoglobin
concentration was not significantly higher in the no ED visit /
hospitalization group. The antimetabolite HU is effective for
reducing complications of SCA including frequent severe
painful VOCs, with one of the proposed mechanisms of action
being increased fetal hemoglobin production, which in turn
reduces sickle hemoglobin polymerization and vaso-
occlusion[9]. The absence of this fetal hemoglobin association
could be due to many factors including confounding by HU
indication, which is an intrinsic limitation of observational
studies. Other potential confounding variables not assessed in
this study include adequacy of HU dosing, duration of HU
therapy and compliance with its use. However, the absence of
an association between higher fetal hemoglobin and fewer
VOCs has also been reported in a contemporary pediatric SCA
cohort that was not treated with HU[28].
The association between painful VOC ED visits and
hospitalizations and mortality as reported by the CSSCD
Table 2. Characteristics associated with patient reported
severe VOCs by multivariable logistic regression.
Independent variable* Coefficient OR (95% CI) † p Value
Hematocrit 0.51 1.99 (1.46-2.71) 0.0008
Ferritin 0.45 1.83 (1.34-2.49) 0.005
HDL-Cholesterol 0.35 1.61 (1.20-2.16) 0.01
* Covariates identified in Table 1 or prior studies (7,9) were included in
multivariable regression models with stepwise elimination of variables that were
not significant in the final model.
† Odds ratio is given for the 75th relative to 25th percentile for continuous variables
calculated as e(coefficient)(75th percentile – 25th percentile).
Abbreviations: OR, odds ratio; HDL, high density lipoprotein; VOC, vaso-occlusive
crisis.
doi: 10.1371/journal.pone.0079923.t002
Table 1. Characteristics of an adult SCA cohort by patient reported severe VOC requiring ED visit/ hospitalization in the past
year.
Parameter Subcategory No ED / Hospitalizations ≥1 ED / Hospitalizations P Value*
  N with data N or Median N with data N or Median  
Age, years (IQR)  104 33.5 (25.5-46.0) 160 31.0 (25.0-40.0) 0.1
Sex, N (%)  104  160  0.7
 Male  51 (49.0)  75 (46.9)  
 Female  53 (51.0)  85 (53.1)  
Hydroxyurea, N (%)  100 38 (38.0) 158 69 (43.7) 0.4
Lifetime transfusions, N (%)  99  136  0.1
 0  10 (10.1)  6 (4.4)  
 1-10  52 (52.5)  64 (47.1)  
 >10  37 (37.4)  66 (48.5)  
α- thalassemia (carrier or trait), N (%)  77 22 (28.6) 130 37 (28.5) 0.9
Asthma, N (%)  101 16 (15.8) 158 26 (16.5) 0.9
Acute chest syndrome, N (%)  102 79 (77.5) 157 135 (86.0) 0.08
Priapism, N (%)  48 22 (45.8) 75 33 (44.0) 0.8
TRV ≥ 2.5, m/sec., N (%)‡  95 56 (59.0) 138 65 (47.1) 0.08
TRV ≥ 3.0, m/sec., N (%)‡  95 22 (23.2) 138 21 (15.2) 0.1
WBC, 109/L (IQR)  100 10.4 (8.5-12.1) 155 10.4 (8.7-12.6) 0.5
Hematocrit, % (IQR)  100 24.6 (21.0-28.1) 155 26.9 (24.3-29.3) 0.0003†
Fetal hemoglobin, % (IQR)  94 6.9 (2.9-11.5) 151 7.7 (3.4-13.5) 0.3
Ferritin, μg/L (IQR)  96 313 (107-1,052) 145 618 (199-1,569) 0.009
Lactate dehydrogenase, U/L (IQR)  94 378 (302-495) 135 346 (256-416) 0.004
Aspartate aminotransferase, U/L (IQR)  99 42 (33.0-51.0) 152 38 (28-54) 0.2
Total bilirubin, mg/dL (IQR)  99 3.1 (1.9-4.1) 152 2.6 (1.7-3.8) 0.2
Uric acid, mg/dL (IQR)  99 6.2 (5.3-7.9) 154 5.9 (4.6-7.3) 0.03
High density lipoprotein cholesterol, mg/dL (IQR)  89 36 (31-43) 142 39 (33-47) 0.02
C-reactive protein, mg/dL (IQR)  88 0.20 (0.20-0.74) 140 0.31 (0.20-0.79) 0.7
Glomerular filtration rate, mL/min./1.73m2 (IQR)  101 160.6 (103.3-199.6) 155 162.3 (122.3-203.4) 0.4
From Wilcoxon or Pearson’s χ2 test between groups of ED visits/Hospitalizations.
† P= < 0.05 after Bonforoni correction
‡ Subjects with an undetectable TRV by echocardiogram were excluded from this analysis (N=5 in the No ED/Hospitalization Group and N=16 in the >1 ED/Hospitalization
Group).
Abbreviations: ED, emergency department; IQR, interquartile range; SCA, sickle cell anemia; TRV, tricuspid regurgitant jet velocity; VOC, vaso-occlusive crisis; WBC, white
blood cell count.
doi: 10.1371/journal.pone.0079923.t001
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almost 20 years ago still remains significant in the
contemporary era of SCD specific therapies. Additionally, our
analysis shows that more frequent severe VOCs requiring
healthcare utilization are associated with mortality independent
of other known risk factors including an elevated TRV, renal
insufficiency and suspected iron burden. These factors could
reflect independent aspects of severe disease and chronic
organ damage in the VOC group. We are unable to comment
on the causes of death in these individuals since most of the
participants were followed and received care in their local
emergency departments or hospitals. Our results suggest that
individuals with a history of health care utilization for severe
pain crises and the presence of any of above mortality risk
factors are at a particularly high risk for death and should be
treated aggressively with appropriate therapies.
Figure 1.  Kaplan Meier (KM) curve showing survival in
sickle cell anemia by severe pain crises requiring an ED
visit/ hospitalization in past year.  
doi: 10.1371/journal.pone.0079923.g001
Table 3. Cox proportional hazards mortality in adults with
SCA.
Risk factor RR (95% CI)* p Value†
ED/Hospitalization, ≥1 in past year 2.68 (1.1-6.5) 0.03
TRV‡ 2.41 (1.5-3.9) <0.0001
Ferritin 4.00 (1.8-9.0) 0.001
GFR 2.73 (1.6-4.6) <0.0001
* RR for ED/hospitalization is given relative to no visits in the past year. RR for
TRV, ferritin and GFR are given for the 75th relative to the 25th percentile.
† From Wald χ2.
‡ 21 subjects with undetectable TRV by echocardiogram were excluded from
analysis. TRV boundaries for the 75th and 25th percentiles were 2.8 m/s and 2.2
m/s, respectively.
Abbreviations: CI, confidence interval; ED, emergency department; GFR,
Modification of Diet in Renal Disease estimated glomerular filtration rate; RR,
relative risk; SCA, sickle cell anemia; TRV, tricuspid regurgitatant jet velocity.
doi: 10.1371/journal.pone.0079923.t003
One limitation of this study was the examination of patient
reported outcomes (severe VOCs), which could introduce the
bias of self-recall and under or overestimation of the number of
actual ED visits/ hospital admissions. Daily pain experienced
by ambulatory adults is underestimated and often managed at
home; therefore ambulatory pain events are not captured by
utilization definitions[6]. The presence of such pattern in our
study could lead to underestimation of frequency of severe
VOC pain crises in our population. Despite these limitations
associated with severe pain crisis as a patient reported
outcome, this definition of pain in SCA (i.e. the pain crisis rate)
has also been useful as a clinical endpoint in drug trials, as a
patient reported component of a forthcoming quality of life
measure for adults with SCD (ASCQ-Me or Adult Sickle Cell
Quality of Life Measurement Information System) and as a
prognostic marker for mortality in the CSSCD[7,9,16,29,30].
The pain crisis rate may also represent a heritable phenotype
for studies of genetic modifiers in SCA[31]. To some extent,
this validates our use of cost effective, patient reported
outcomes for a history of pain to assess SCA disease severity.
Our findings suggest that the above lab studies are
biomarkers indicative of SCA clinical severity that contributes to
premature mortality in contemporary patients receiving modern
therapies. Although these associations might represent
epiphenomena of clinical severity, they provide several
hypothetical targets for future investigation of interventions to
improve longevity in SCA.
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pain crisis events defined by ED visits and




The authors would like to thank the study participants, the NIH
Clinical Center nursing staff, and Britny Hall. Dr. Lena Diaw is
also thanked for critically reviewing this manuscript. Trial
Registration: Clinicaltrials.gov identifier: NCT00011648.
Author Contributions
Conceived and designed the experiments: JGT DD. Performed
the experiments: JN DA CS MPL AC M. Hall GJK JGT.
Analyzed the data: DD ZW MK M. Hildesheim GJK JGT. Wrote
the manuscript: DD JGT.
Pain and Mortality in Sickle Cell Anemia
PLOS ONE | www.plosone.org 5 November 2013 | Volume 8 | Issue 11 | e79923
References
1. Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG (2009)
The cost of health care for children and adults with sickle cell disease.
Am J Hematol 84: 323-327. doi:10.1002/ajh.21408. PubMed:
19358302.
2. Steinberg MH (1999) Management of sickle cell disease. N Engl J Med
340: 1021-1030. doi:10.1056/NEJM199904013401307. PubMed:
10099145.
3. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA
(2010) Acute care utilization and rehospitalizations for sickle cell
disease. JAMA 303: 1288-1294. doi:10.1001/jama.2010.378. PubMed:
20371788.
4. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF et al.
(1991) Pain in sickle cell disease. Rates and risk factors. N Engl J Med
325: 11-16. doi:10.1056/NEJM199107043250103. PubMed: 1710777.
5. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C (2005) Outcome
of sickle cell anemia: a 4-decade observational study of 1056 patients.
Medicine (Baltimore) 84: 363-376. doi:10.1097/01.md.
0000189089.45003.52. PubMed: 16267411.
6. Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, Roberts JD et al.
(2008) Daily assessment of pain in adults with sickle cell disease. Ann
Intern Med 148: 94-101. doi:
10.7326/0003-4819-148-2-200801150-00004. PubMed: 18195334.
7. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O et al. (1994)
Mortality in sickle cell disease. Life expectancy and risk factors for early
death. N Engl J Med 330: 1639-1644. doi:10.1056/
NEJM199406093302303. PubMed: 7993409.
8. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E et al. (1998)
Prevention of a first stroke by transfusions in children with sickle cell
anemia and abnormal results on transcranial Doppler ultrasonography.
N Engl J Med 339: 5-11. doi:10.1056/NEJM199807023390102.
PubMed: 9647873.
9. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB et al. (1995)
Effect of hydroxyurea on the frequency of painful crises in sickle cell
anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle
Cell Anemia. N Engl J Med 332: 1317-1322. doi:10.1056/
NEJM199505183322001. PubMed: 7715639.
10. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J et al. (1986)
Prophylaxis with oral penicillin in children with sickle cell anemia. A
randomized trial. N Engl J Med 314: 1593-1599. doi:10.1056/
NEJM198606193142501. PubMed: 3086721.
11. Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD et al.
(2010) The risks and benefits of long-term use of hydroxyurea in sickle
cell anemia: A 17.5 year follow-up. Am J Hematol 85: 403-408.
PubMed: 20513116.
12. Miller ST, Wright E, Abboud M, Berman B, Files B et al. (2001) Impact
of chronic transfusion on incidence of pain and acute chest syndrome
during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J
Pediatr 139: 785-789. doi:10.1067/mpd.2001.119593. PubMed:
11743502.
13. Castro O, Hoque M, Brown BD (2003) Pulmonary hypertension in
sickle cell disease: cardiac catheterization results and survival. Blood
101: 1257-1261. doi:10.1182/blood-2002-03-0948. PubMed: 12393669.
14. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF et al. (2004)
Pulmonary hypertension as a risk factor for death in patients with sickle
cell disease. N Engl J Med 350: 886-895. doi:10.1056/NEJMoa035477.
PubMed: 14985486.
15. Parent F, Bachir D, Inamo J, Lionnet F, Driss F et al. (2011) A
hemodynamic study of pulmonary hypertension in sickle cell disease. N
Engl J Med 365: 44-53. doi:10.1056/NEJMoa1005565. PubMed:
21732836.
16. Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ et al. (2011)
Hospitalization for pain in patients with sickle cell disease treated with
sildenafil for elevated TRV and low exercise capacity. Blood 118:
855-864. doi:10.1182/blood-2010-09-306167. PubMed: 21527519.
17. Minniti CP, Machado RF, Coles WA, Sachdev V, Gladwin MT et al.
(2009) Endothelin receptor antagonists for pulmonary hypertension in
adult patients with sickle cell disease. Br J Haematol 147: 737-743. doi:
10.1111/j.1365-2141.2009.07906.x. PubMed: 19775299.
18. Taylor JG, Ackah D, Cobb C, Orr N, Percy MJ et al. (2008) Mutations
and polymorphisms in hemoglobin genes and the risk of pulmonary
hypertension and death in sickle cell disease. Am J Hematol 83: 6-14.
doi:10.1002/ajh.21035. PubMed: 17724704.
19. Liu YT, Old JM, Miles K, Fisher CA, Weatherall DJ et al. (2000) Rapid
detection of alpha-thalassaemia deletions and alpha-globin gene
triplication by multiplex polymerase chain reactions. Br J Haematol 108:
295-299. doi:10.1046/j.1365-2141.2000.01870.x. PubMed: 10691858.
20. Taylor JG, Nolan VG, Mendelsohn L, Kato GJ, Gladwin MT et al.
(2008) Chronic hyper-hemolysis in sickle cell anemia: association of
vascular complications and mortality with less frequent vasoocclusive
pain. PLOS ONE 3: e2095. doi:10.1371/journal.pone.0002095.
PubMed: 18461136.
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N et al. (1999) A
more accurate method to estimate glomerular filtration rate from serum
creatinine: a new prediction equation. Modification of Diet in Renal
Disease Study Group. Ann Intern Med 130: 461-470. doi:
10.7326/0003-4819-130-6-199903160-00002. PubMed: 10075613.
22. Nagel RL, Fabry ME, Steinberg MH (2003) The paradox of hemoglobin
SC disease. Blood Rev 17: 167-178. doi:10.1016/
S0268-960X(03)00003-1. PubMed: 12818227.
23. Billett HH, Kim K, Fabry ME, Nagel RL (1986) The percentage of dense
red cells does not predict incidence of sickle cell painful crisis. Blood
68: 301-303. PubMed: 3719102.
24. Ballas SK, Larner J, Smith ED, Surrey S, Schwartz E et al. (1988)
Rheologic predictors of the severity of the painful sickle cell crisis.
Blood 72: 1216-1223. PubMed: 3167204.
25. Shalev H, Kapelushnik J, Moser A, Knobler H, Tamary H (2007)
Hypocholesterolemia in chronic anemias with increased erythropoietic
activity. Am J Hematol 82: 199-202. doi:10.1002/ajh.20804. PubMed:
17039515.
26. Zorca S, Freeman L, Hildesheim M, Allen D, Remaley AT et al. (2010)
Lipid levels in sickle-cell disease associated with haemolytic severity,
vascular dysfunction and pulmonary hypertension. Br J Haematol 149:
436-445. doi:10.1111/j.1365-2141.2010.08109.x. PubMed: 20230401.
27. Sasaki J, Waterman MR, Buchanan GR, Cottam GL (1983) Plasma
and erythrocyte lipids in sickle cell anaemia. Clin Lab Haematol 5:
35-44. PubMed: 6851435.
28. Bean CJ, Boulet SL, Ellingsen D, Pyle ME, Barron-Casella EA et al.
(2012) Heme oxygenase-1 gene promoter polymorphism is associated
with reduced incidence of acute chest syndrome among children with
sickle cell disease. Blood 120: 3822-3828. doi:10.1182/
blood-2011-06-361642. PubMed: 22966170.
29. Charache S, Terrin ML, Moore RD, Dover GJ, McMahon RP et al.
(1995) Design of the multicenter study of hydroxyurea in sickle cell
anemia. Investigators of the Multicenter Study of Hydroxyurea. Control
Clin Trials 16: 432-446. doi:10.1016/S0197-2456(95)00098-4. PubMed:
8925656.
30. Hoots WK, Shurin SB (2012) Future directions of sickle cell disease
research: the NIH perspective. Pediatr Blood Cancer 59: 353-357. doi:
10.1002/pbc.24180. PubMed: 22517801.
31. Lettre G (2012) The Search for Genetic Modifiers of Disease Severity in
the beta-Hemoglobinopathies. Cold Spring Harbor Perspectives Med 2.
Pain and Mortality in Sickle Cell Anemia
PLOS ONE | www.plosone.org 6 November 2013 | Volume 8 | Issue 11 | e79923
